(Q34641224)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869151%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

title

JAK/STAT signaling in hematological malignancies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869151%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869151%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Stefan N Constantinescu

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869151%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

W Vainchenker

series ordinal

1

1 reference

3 August 2017

S N Constantinescu

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

6 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869151%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869151%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869151%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869151%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

2601-2613

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869151%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2012.347

10 February 2020

exact match

0 references

cites work

A protein tyrosine kinase in the interferon alpha/beta signaling pathway

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Erythropoietin receptor activation by a ligand-induced conformation change

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Model for growth hormone receptor activation based on subunit rotation within a receptor dimer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Structural Linkage between Ligand Discrimination and Receptor Activation by Type I Interferons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Stats: transcriptional control and biological impact

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

A gain-of-function mutation of JAK2 in myeloproliferative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Identification of somatic JAK1 mutations in patients with acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

JAK mutations in high-risk childhood acute lymphoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Cytokine receptor signal transduction and the control of hematopoietic cell development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Novel role of Janus kinase 1 in the regulation of oncostatin M receptor surface expression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Janus kinases affect thrombopoietin receptor cell surface localization and stability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Efficiency of signalling through cytokine receptors depends critically on receptor orientation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Thrombopoietin signal transduction requires functional JAK2, not TYK2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Granulocyte colony-stimulating factor and its receptor in normal myeloid cell development, leukemia and related blood cell disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

The Erythropoietin Receptor: Structure, Activation and Intracellular Signal Transduction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3 intact

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Janus kinases in immune cell signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Distinct roles for STAT1, STAT3, and STAT5 in differentiation gene induction and apoptosis inhibition by interleukin-9

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Suppressor of cytokine signaling 3 controls lysosomal routing of G-CSF receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

TYK2 activity promotes ligand-induced IFNAR1 proteolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Differential roles of SOCS family members in EpoR signal transduction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary myelofibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

PIAS proteins as regulators of small ubiquitin-related modifier (SUMO) modifications and transcription

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

PIASy represses CCAAT/enhancer-binding protein delta (C/EBPdelta) transcriptional activity by sequestering C/EBPdelta to the nuclear periphery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3'-kinase/protein kinase B signaling pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

JAK kinases overexpression promotes in vitro cell transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Phosphorylation of Jak2 on Ser(523) inhibits Jak2-dependent leptin receptor signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Critical requirement for Stat5 in a mouse model of polycythemia vera

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Stat5a/b are essential for normal lymphoid development and differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Mutations of ASXL1 gene in myeloproliferative neoplasms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Mutation in TET2 in myeloid cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Frequent pathway mutations of splicing machinery in myelodysplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

The myeloproliferative disorder associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Cell signalling: PRMT5 restricts ERK activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Protein arginine methyltransferase 5 (PRMT5) signaling suppresses protein kinase Cδ- and p38δ-dependent signaling and keratinocyte differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Germline JAK2 mutation in a family with hereditary thrombocytosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Activating mutations in human acute megakaryoblastic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Activating alleles of JAK3 in acute megakaryoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Distinguishing cancer-associated missense mutations from common polymorphisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Somatic STAT3 mutations in large granular lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

MPLW515L mutation in acute megakaryoblastic leukaemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

G-CSF and its receptor in myeloid malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

The role of signal transducer and activator of transcription factors in leukemogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Signal transduction of oncogenic Flt3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Lnk constrains myeloproliferative diseases in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

SOCS1 links cytokine signaling to p53 and senescence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

CD45 tyrosine phosphatase inhibits erythroid differentiation of umbilical cord blood CD34+ cells associated with selective inactivation of Lyn.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Methylation status of nine tumor suppressor genes in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Ubiquitination and degradation of the thrombopoietin receptor c-Mpl.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Cbl and human myeloid neoplasms: the Cbl oncogene comes of age.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Signalling and survival pathways in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Differential STAT5 signaling by ligand-dependent and constitutively active cytokine receptors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Janus-activated kinase 2 inhibitors: a new era of targeted therapies providing significant clinical benefit for Philadelphia chromosome-negative myeloproliferative neoplasms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Critical Role of Thrombopoietin in Maintaining Adult Quiescent Hematopoietic Stem Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Regulation of hematopoietic stem cells by their mature progeny

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

EZH2 mutational status predicts poor survival in myelofibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.347

31 March 2020

Identifiers

DOI

10.1038/ONC.2012.347

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869151%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

10 February 2020

0 references

1 reference